EcoDrugPlus

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSDLAG00005015181
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSDLAG00005014004
Gene Symbol: P2RX3B
1 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSDLAG00005011780
Gene Symbol: P2RX7
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSDLAG00005033432
Gene Symbol: P2RY1
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSDLAG00005006198
Gene Symbol: P2RY12
1 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSDLAG00005021971
Gene Symbol: RIPK1L
1 Cross references
198 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSDLAG00005006733
Gene Symbol: RET
1 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSDLAG00005033103
Gene Symbol: RARB
1 Cross references
394 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSDLAG00005014702
Gene Symbol: RPL11
1 Cross references
288 Possible Orthologues:

Ribosomal Protein L13a

Ensembl ID : ENSDLAG00005000624
Gene Symbol: RPL13A
1 Cross references
369 Possible Orthologues:

Ribosomal Protein L13a

Ensembl ID : ENSDLAG00005032540
Gene Symbol: RPL13A
1 Cross references
369 Possible Orthologues:

Ribosomal Protein L15

Ensembl ID : ENSDLAG00005012824
Gene Symbol: RPL15
1 Cross references
376 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).